<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03416751</url>
  </required_header>
  <id_info>
    <org_study_id>BAJAJ0021A</org_study_id>
    <nct_id>NCT03416751</nct_id>
  </id_info>
  <brief_title>Fecal Microbial Transplant for Alcohol Misuse in Cirrhosis</brief_title>
  <official_title>Fecal Microbial Transplant for Alcohol Misuse in Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hunter Holmes Mcguire Veteran Affairs Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>OpenBiome</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hunter Holmes Mcguire Veteran Affairs Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is an epidemic of alcohol use disorder in the US. Alcoholism is an epidemic that spans
      all ages and socio-economic strata, which has a major impact on healthcare expenditure.
      Alcohol-associated liver disease can take the form of mild fatty liver, chronic liver disease
      including cirrhosis and a very acute active form known as alcoholic hepatitis. However, most
      patients with alcohol abuse issues with cirrhosis do not develop alcoholic hepatitis and are
      not willing to quit drinking. These patients are neither liver transplant candidates due to
      their drinking nor have any recourse to therapies directed towards the liver as is the case
      with alcoholic hepatitis. This is very large proportion of cirrhotic patients who do not have
      many therapeutic options.

      Prior studies have demonstrated that these patients have an altered gut-liver axis which is
      exacerbated by dysbiosis and a higher production of potentially toxic secondary bile acids.
      These secondary bile acids in turn have the potential to worsen the already impaired gut
      barrier in these patients, creating a vicious cycle of inflammation and further liver injury
      that is led by the altered microbial composition. A gut-based strategy that has the
      capability of &quot;resetting&quot; this dysbiosis could help in the amelioration of this inflammatory
      load and improve the prognosis of these patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, single-blind, placebo-controlled safety, tolerability study with exploratory
      endpoints and pathophysiological evaluation of the FMT

      Two groups of outpatients with cirrhosis will be randomized using random sequence generator
      into no-treatment and FMT groups.

      Once patients are randomized 1:1 into group 1 (FMT) and group 2 (Placebo), both will be
      followed over 31 days and will include a 6 month visit to collect samples, perform
      questionnaires and to assess SAEs.

      There is an epidemic of alcohol use disorder in the US. Alcoholism is an epidemic that spans
      all ages and socio-economic strata, which has a major impact on healthcare expenditure.
      Alcohol-associated liver disease can take the form of mild fatty liver, chronic liver disease
      including cirrhosis and a very acute active form known as alcoholic hepatitis. However, most
      patients with alcohol abuse issues with cirrhosis do not develop alcoholic hepatitis and are
      not willing to quit drinking. These patients are neither liver transplant candidates due to
      their drinking nor have any recourse to therapies directed towards the liver as is the case
      with alcoholic hepatitis. This is very large proportion of cirrhotic patients who do not have
      many therapeutic options.

      Prior studies have demonstrated that these patients have an altered gut-liver axis which is
      exacerbated by dysbiosis and a higher production of potentially toxic secondary bile acids.
      These secondary bile acids in turn have the potential to worsen the already impaired gut
      barrier in these patients, creating a vicious cycle of inflammation and further liver injury
      that is led by the altered microbial composition. The investigators believe that a gut-based
      strategy that has the capability of &quot;resetting&quot; this dysbiosis can help in the amelioration
      of this inflammatory load and improve the prognosis of these patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 5, 2018</start_date>
  <completion_date type="Anticipated">March 5, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 5, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants with a related serious adverse event</measure>
    <time_frame>15 days</time_frame>
    <description>Related SAE to FMT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of participants with newly acquired transmissible infectious diseases</measure>
    <time_frame>15 days</time_frame>
    <description>Related transmissible infectious disease to FMT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of participants with a related adverse event</measure>
    <time_frame>15 days</time_frame>
    <description>Related adverse event that does not meet the criteria for a serious adverse event</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with a related serious adverse event</measure>
    <time_frame>30 days and 6 months</time_frame>
    <description>Related SAE to FMT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with a related adverse event</measure>
    <time_frame>30 days and 6 months</time_frame>
    <description>Related adverse event that does not meet the criteria for a serious adverse event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with newly acquired transmissible infectious diseases</measure>
    <time_frame>30 days and 6 months</time_frame>
    <description>Related transmissible infectious disease to FMT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composition of microbial change</measure>
    <time_frame>day 15, 30 and 6 months post-intervention</time_frame>
    <description>UNIFRAC and LEFSe pre vs post FMT on stool microbiota compared to baseline and to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUDIT questionnaire</measure>
    <time_frame>day 15, 30 and 6 months post-intervention</time_frame>
    <description>defining changes in alcohol abuse severity compared to baseline and to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alcohol craving questionnaire</measure>
    <time_frame>day 15, 30 and 6 months post-intervention</time_frame>
    <description>defining changes in the cravings for alcohol compared to baseline and to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic inflammation changes</measure>
    <time_frame>day 15, 30 and 6 months post-intervention</time_frame>
    <description>Inflammatory cytokines (IL-6, TNF, IL-1b) compared to baseline and to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognition change using PHES</measure>
    <time_frame>day 15, 30 and 6 months post-intervention</time_frame>
    <description>Psychometric hepatic encephalopathy score compared to baseline and to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognition change using EncephalApp stroop</measure>
    <time_frame>day 15, 30 and 6 months post-intervention</time_frame>
    <description>EncephalApp stroop compared to baseline and to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life using Sickness Impact Profile</measure>
    <time_frame>day 15, 30 and 6 months post-intervention</time_frame>
    <description>Sickness Impact Profile compared to baseline and to placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Cirrhosis</condition>
  <condition>Alcohol Abuse</condition>
  <arm_group>
    <arm_group_label>Fecal Microbial transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will get one-dose of 90ml of FMT enema on day 1 that has been received from OpenBiome using a rational donor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will get one-dose of 90ml of saline enema on day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fecal Microbial Transplant</intervention_name>
    <description>Fecal transplant from a donor in the OpenBiome Registry</description>
    <arm_group_label>Fecal Microbial transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo enemas</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        A. Cirrhosis diagnosed by any of the following in a patient with chronic liver disease:

          1. Liver Biopsy

          2. Radiologic evidence of varices, cirrhosis or portal hypertension

          3. Laboratory evidence of platelet count &lt;100,000 or AST/ALT ratio&gt;1

          4. Endoscopic evidence of varices or portal gastropathy

          5. Fibroscan B. Age between 21 and 75 C. Able to give written, informed consent
             (demonstrated by mini-mental status exam&gt;25 at the time of consenting) D. Subject must
             have alcohol as a cause of cirrhosis

        i. Continued sustained drinking pattern with AUDIT score â‰¥8 in the last month and
        fulfilling DSM-V criteria for alcohol misuse ii. Unable or unwilling to get mental health
        attention to quit alcohol (at least 3-months period of referrals to Substance abuse
        programs or other alcohol treatment approaches) iii. Adult companion who can accompany
        patient and provide insight into alcohol drinking patterns

        Exclusion Criteria:

        A. MELD score &gt;17 B. Child Class C C. WBC count &lt;1000 cells/mm3 D. Platelet
        count&lt;50,000/mm3 E. TIPS in place for less than a month F. HE episode within a month prior
        to the study G. Currently on absorbable antibiotics H. Infection at the time of the FMT
        (diagnosed by blood culture positivity, urinalysis, paracentesis as needed) I. Patients who
        are aged &gt;75 years J. Patients who are pregnant or nursing (will be checked using a urine
        pregnancy test) K. Patients who are incarcerated L. Patients who are incapable of giving
        their own informed consent

        M. Patients who are immuno-compromised due to the following reasons:

          1. HIV infection (any CD4 count)

          2. Inherited/primary immune disorders

          3. Current or recent (&lt;3 months) treatment with anti-neoplastic agent

          4. Current or recent (&lt;3 months) treatment with any immunosuppressant medications
             [including but not limited to monoclonal antibodies to B and T cells, anti-TNF agents,
             glucocorticoids, antimetabolites (azathioprine, 6-mercaptopurine), calcineurin
             inhibitors (tacrolimus, cyclosporine), mycophenolate mofetil]. Subjects who are
             otherwise immunocompetent and have discontinued any immunosuppressant medications 3 or
             more months prior to enrollment may be eligible to enroll.

        N. Patients with a history of severe (anaphylactic) food allergy O. Patients who have
        previously undergone FMT P. Patients on renal replacement therapy Q. Patients who are
        unwilling or unable to hold the enemas R. Patients with untreated, in-situ colorectal
        cancer S. Patients with a history of chronic intrinsic GI diseases such as inflammatory
        bowel disease (ulcerative colitis, Crohn's disease or microscopic colitis), eosinophilic
        gastroenteritis, celiac disease or irritable bowel syndrome T. Major gastro-intestinal or
        intra-abdominal surgery in the last three months U. Unable to comply with protocol
        requirements V. Patients who are American Society of Anesthesiologists (ASA) Physical
        Status classification IV and V W. Patients with acute illness or fever on the day of
        planned FMT will be excluded with the option of including that subject at a future date X.
        Any conditions for which, in opinion of MD, the treatment may pose a health risk Y. Grade
        2-4 or complicated hemorrhoids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jasmohan S Bajaj, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hunter Holmes McGuire VA Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jasmohan S Bajaj, MD</last_name>
    <phone>804 675 5802</phone>
    <email>jsbajaj@vcu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jill Meador, RN</last_name>
    <phone>804 675 6407</phone>
    <email>jill.meador@va.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hunter Holmes McGuire VA Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jasmohan S Bajaj, MD</last_name>
      <phone>804-675-5021</phone>
      <email>jsbajaj@vcu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jill Meador, RN</last_name>
      <phone>804 675 6407</phone>
      <email>jill.meador@va.gov</email>
    </contact_backup>
    <investigator>
      <last_name>Jasmohan S Bajaj, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Fuchs, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Binu John, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Puneet Puri, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cynthia Solomon, NP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Veda Forte, NP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2018</study_first_submitted>
  <study_first_submitted_qc>January 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2018</study_first_posted>
  <last_update_submitted>February 7, 2018</last_update_submitted>
  <last_update_submitted_qc>February 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

